Neuroscience-focused biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) announced on Tuesday that it will present new data from the Phase 2 SAVITRI study of osavampator in adults with major depressive disorder at Psych Congress 2025, taking place from 17-21 September in San Diego.

The results will be shared on 18 September from 4:30 pm – 5:45 pm PT as part of a poster presentation session entitled 'Latest Discoveries & Emerging Trends in MDD'.

Osavampator (NBI-1065845) is an investigational selective positive allosteric modulator of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPA-PAM) in development as a potential adjunctive treatment for adults with major depressive disorder (MDD) who have an inadequate response to oral antidepressant treatment.

Following the announcement of positive top-line data from the Phase 2 SAVITRI study, Neurocrine initiated a Phase 3 registrational programme of osavampator in January 2025, which includes five studies that are currently active and enrolling.